Lithium-Associated Generalized Ostraceous Psoriasis Treated with Adalimumab: A Case Report

Abstract

Ostraceous psoriasis is a rare variant of psoriasis, characterized by severe hyperkeratotic lesions resembling an oyster shell. Adalimumab is a biological agent that antagonizes tumor necrosis factor (TNF) and is used clinically in plaque psoriasis. Some medications such as lithium carbonate (LC) may aggravate or trigger psoriasis. Here, we describe a case of generalized ostraceous psoriasis associated with lithium carbonate, whose lesions completely improved after discontinuing lithium carbonate and using adalimumab.

Keywords:

• ostraceous psoriasis
• adalimumab
• lithium carbonate

Ethics Approval and Consent for Publication

This case report has been performed in accordance with the principles stated in the Declaration of Helsinki. A written informed consent, provided by the Department of Dermatology and Venereology, West China Hospital, Sichuan University for publication of this case report and including photography and medical information, was signed by the patient. Institutional approval was not required to publish the case details.

Acknowledgment

The authors would like to thank the patient recruited for participation in this study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors have declared no conflicts of interest in this work.

Additional information

Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.